Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10504514 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL9575990 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10504300 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL276898 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10503237 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10502475 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL276335 | 0.97 | — | — | |
| SCHEMBL276720 | 0.90 | — | — | |
| SCHEMBL4275505 | 0.79 | OPRM1 (0.48) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL4269729 | 0.79 | OPRM1 (0.48) | OPRM1ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-4806675-A | CATALYTIC ESTERIFICATION WITH HYDROXYALKANOIC AND THIOALKANOIC ACIDS; HEAT AND OXIDATION RESISTANCE | MALLINCKRODT, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4794138-A | STABILIZERS OF ORGANIC MATERIAL NORMALLY SUSCEPTIBLE TO OXIDATIVE AND/OR THERMAL DETERIORATION | MALLINCKRODT, INC. (US) | 1988-12-27 | — | — | US | disclosed |
| US-4772741-A | STABILIZERS FOR POLYMERS | MILLINCKRODT, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4734519-A | STABILIZERS | MALLINCKRODT, INC. (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0250087-A1 | Pentaerythritol co-esters | MALLINCKRODT, INC. (US) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | OPRM1 616/4885ADH1B 2272/4885ADH1C 1599/4885 |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | OPRM1 1047/4885ADH1B 484/4885ADH1C 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.